ArticlePsycho-oncology2026
How Survivors of Colorectal Cancer Experience ctDNA Testing and Fear of Recurrence.
Article in Psycho-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirculating tumor DNA (ctDNA) is a novel prognostic biomarker indicating minimal residual disease and high recurrence risk. In three randomised DYNAMIC trials, ctDNA was used to guide adjuvant chemotherapy (ACT) for early-stage colorectal cancer. While clinical applications of ctDNA are being established, the psychosocial impact, particularly on fear of cancer recurrence (FCR), is less understood.
objectiveTo explore the psychosocial impact, especially FCR, of ctDNA-informed ACT decisions among a subset of DYNAMIC trial participants.
methodsA qualitative study using semi-structured interviews was conducted with English-speaking, recurrence-free patients from the DYNAMIC trials, across ctDNA-guided and standard-care groups. Interviews were audio-recorded, transcribed, and thematically analyzed.
resultsTwenty-eight patients participated (median age 64 years; 64% male; equal numbers with early-stage colon and rectal cancer). Eight received a positive ctDNA result, 11 a negative result, and 9 were blinded to their result. Three themes emerged: (1) Limited Understanding of ctDNA Results: Many patients had poor recall or understanding of the test and its prognostic meaning. (2) Trust in Clinician-Led Decision-Making: Strong reliance on clinicians to interpret results and guide ACT decisions. (3) FCR - Episodic, Context dependent: Fear was intermittent, typically arising around scans, new symptoms, or others' diagnoses, and was not influenced by ctDNA knowledge.
conclusionIn this cohort, on average 5 years from trial entry, ctDNA-informed ACT decisions did not increase FCR or cause long term psychosocial harm. As ctDNA testing enters routine practice, clear communication strategies will be essential to ensure patients understand results while maintaining trust in clinician-patient decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.